EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access

18F-labeled prostate-specific membrane antigen positron emission tomography/ computed tomography vs. magnetic resonance imaging in diagnosis of prostate cancer: A meta-analysis

Hailong Feng, Yanqing Su, Fuzhi Lu

Canadian Urological Association Journal · 04.05.2026 · 20 (9)

DOI: 10.5489/cuaj.9534 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Canadian Urological Association Journal, online erschienen am 04.05.2026. Verfasst von Hailong Feng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Second Outpatient Department of Directly Affiliated Institutions, Hebei Province, Shijiazhuang City, China. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The accurate diagnosis of prostate cancer remains a clinical challenge, with both multiparametric magnetic resonance imaging (mpMRI) and 18F-prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) emerging as important imaging modalities. This meta-analysis aimed to compare the diagnostic performance of 18F-PSMA PET/CT vs. MRI for detecting prostate cancer.

Methods

A comprehensive systematic review and meta-analysis was conducted following PRISMA guidelines. Multiple databases were searched through February 2025. Studies comparing 18F-PSMA PET/CT with MRI for prostate cancer diagnosis using histopathology as the reference standard were included. Random-effects models were used to pool sensitivity data, with heterogeneity assessed using I² statistics.

Results

Six studies comprising 310 patients were included. The pooled sensitivity for MRI was 0.81 (95% confidence interval [CI] 0.08-0.99) with substantial heterogeneity (I²=93.8%). For 18F-PSMA PET/CT, the overall sensitivity was 0.50 (95% CI 0.12-0.87) with high heterogeneity (I²=96.0%). Subgroup analysis showed 18F-PSMA PET had a pooled sensitivity of 0.50 (95% CI 0.12-0.87), while MRI demonstrated 0.81 (95% CI 0.42-0.96). No significant publication bias was detected.

Conclusions

Both imaging modalities showed variable diagnostic performance across studies. The combination of PSMA PET/CT and MRI may provide complementary information for optimal prostate cancer detection, although substantial heterogeneity suggests the need for standardized protocols and larger prospective trials.

Autor:innen und Institutionen

  • Department of Radiology, Second Outpatient Department of Directly Affiliated Institutions, Hebei Province, Shijiazhuang City, China.

Zitieren

APA

Feng, H., Su, Y., & Lu, F. (2026). 18F-labeled prostate-specific membrane antigen positron emission tomography/ computed tomography vs. magnetic resonance imaging in diagnosis of prostate cancer: A meta-analysis. Canadian Urological Association Journal, 20(9). https://doi.org/10.5489/cuaj.9534

Vancouver

Feng H, Su Y, Lu F. 18F-labeled prostate-specific membrane antigen positron emission tomography/ computed tomography vs. magnetic resonance imaging in diagnosis of prostate cancer: A meta-analysis. Canadian Urological Association Journal. 2026;20(9). doi:10.5489/cuaj.9534

BibTeX
@article{Feng2026,
  author = {Feng, Hailong and Su, Yanqing and Lu, Fuzhi},
  title = {18F-labeled prostate-specific membrane antigen positron emission tomography/ computed tomography vs. magnetic resonance imaging in diagnosis of prostate cancer: A meta-analysis},
  journal = {Canadian Urological Association Journal},
  year = {2026},
  volume = {20},
  number = {9},
  doi = {10.5489/cuaj.9534}
}
Kostenlos starten →